Phase I study of camrelizumab in patients with advanced solid tumors.
Ma Y, Cao J, Zhang Y, Liu Q, Fang W, Yang Y, Zhao Y, Yang Q, Zhao H, Zhang L.
Ma Y, et al. Among authors: yang q, yang y.
Signal Transduct Target Ther. 2023 Feb 1;8(1):47. doi: 10.1038/s41392-022-01213-6.
Signal Transduct Target Ther. 2023.
PMID: 36725836
Free PMC article.
Clinical Trial.
No abstract available.